{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:23:31Z","timestamp":1787775811756,"version":"build-2784847793"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Insulin resistance plays the central role in the pathophysiology of polycystic ovary syndrome (PCOS). While metformin is widely used, its metabolic and androgen-lowering benefits are modest and often limited by tolerability, highlighting the need to evaluate newer therapeutic agents targeting insulin resistance in PCOS. Dapagliflozin complements metformin\u2019s effects through an insulin-independent mechanism of action and may be beneficial in improving metabolic outcomes in PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Women diagnosed with PCOS based on Rotterdam criteria were randomly allocated to receive either dapagliflozin (10 mg daily) plus metformin (2000 mg\/day) or metformin (2000 mg\/day) alone, over a 12-week period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>At 12 weeks, there were no statistically significant differences between the dapagliflozin plus metformin group and the metformin alone group in improving insulin resistance or biochemical hyperandrogenism. While within-group changes were statistically significant, the differences between the two arms did not achieve statistical significance. Mild adverse effects, including urinary tract infections and vaginal irritation, were reported more in the dapagliflozin plus metformin group than the metformin alone group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In overweight and obese women with PCOS, the addition of dapagliflozin to metformin did not result in significant improvement in insulin resistance or hyperandrogenaemia over metformin alone and was associated with a higher rate of adverse effects. Larger and longer-term trials are needed to fully clarify their role in routine clinical care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijem.ijem_635_25","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:01:07Z","timestamp":1772204467000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Dapagliflozin Plus Metformin Versus Metformin Alone in Overweight and Obese Patients with Polycystic Ovary Syndrome - An Open-Label, Parallel, Randomized Controlled Trial"],"prefix":"10.4103","volume":"30","author":[{"given":"Vishal","family":"Agarwal","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sambit","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayanidhi","family":"Meher","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devadarshini","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K.","family":"Sahu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhadra","family":"Priyadarshini","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam J.","family":"Agarwal","sequence":"additional","affiliation":[{"name":"School of Public Health, KIIT Deemed to be University, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Prusty","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijay K.","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amogh S.","family":"Chappalagavi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheenam","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"R1-20260302","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00404-024-07607-x","article-title":"Global prevalence of polycystic ovary syndrome in women worldwide: A comprehensive systematic review and meta-analysis","volume":"310","author":"Salari","year":"2024","journal-title":"Arch Gynecol Obstet"},{"key":"R2-20260302","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpag.2011.03.002","article-title":"Prevalence of polycystic ovarian syndrome in Indian adolescents","volume":"24","author":"Nidhi","year":"2011","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R3-20260302","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/2230-8210.131162","article-title":"A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India","volume":"18","author":"Joshi","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"R4-20260302","first-page":"e47408","article-title":"Polycystic ovary syndrome: A literature review with a focus on diagnosis, pathophysiology, and management","volume":"15","author":"Waghmare","year":"2023","journal-title":"Cureus"},{"key":"R5-20260302","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr Rev"},{"issue":"(Suppl 2)","key":"R6-20260302","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/sj.ijo.0801282","article-title":"Obesity, insulin, sex steroids and ovulation","volume":"24","author":"Nestler","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"(4 Suppl)","key":"R7-20260302","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.fertnstert.2008.06.037","article-title":"Abdominal fat distribution and insulin resistance in Indian women with polycystic ovarian syndrome","volume":"91","author":"Kalra","year":"2009","journal-title":"Fertil Steril"},{"key":"R8-20260302","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/AOG.0000000000002698","article-title":"Polycystic ovary syndrome","volume":"132","author":"Azziz","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R9-20260302","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"R10-20260302","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"issue":"(2)","key":"R11-20260302","first-page":"CD007506","article-title":"Lifestyle changes in women with polycystic ovary syndrome","author":"Moran","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R12-20260302","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/oby.22980","article-title":"Weight reduction through a cognitive behavioral therapy lifestyle intervention in PCOS: The primary outcome of a randomized controlled trial","volume":"28","author":"Jiskoot","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"R13-20260302","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2004-1965","article-title":"Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome","volume":"90","author":"Ortega-Gonz\u00e1lez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20260302","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13063-020-4121-x","article-title":"Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: A randomized controlled trial","volume":"21","author":"Ferreira-Hermosillo","year":"2020","journal-title":"Trials"},{"key":"R15-20260302","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1210\/clinem\/dgab408","article-title":"Exenatide, dapagliflozin, or phentermine\/topiramate differentially affect metabolic profiles in polycystic ovary syndrome","volume":"106","author":"Elkind-Hirsch","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-20260302","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R17-20260302","doi-asserted-by":"crossref","first-page":"1003238","DOI":"10.3389\/fendo.2022.1003238","article-title":"Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-centre, open-labeled prospective randomized controlled trial","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R18-20260302","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/cen.13968","article-title":"Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study","volume":"90","author":"Javed","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R19-20260302","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycaemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20260302","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"R21-20260302","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"R22-20260302","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"R23-20260302","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R24-20260302","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s40618-017-0708-9","article-title":"Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Systematic review and meta-analysis","volume":"40","author":"Rocha","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"R25-20260302","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/biomedicines11040998","article-title":"The potential of SGLT-2 inhibitors in the treatment of polycystic ovary syndrome: The current status and future perspectives","volume":"11","author":"Rakic","year":"2023","journal-title":"Biomedicines"},{"key":"R26-20260302","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.3390\/ijms22052576","article-title":"Impact of SGLT-2 inhibition on cardiometabolic abnormalities in a rat model of polycystic ovary syndrome","volume":"22","author":"Pruett","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R27-20260302","doi-asserted-by":"crossref","first-page":"20503121241308997","DOI":"10.1177\/20503121241308997","article-title":"Effects of SGLT-2 inhibitors on clinical and biological hyperandrogenism and menstruation irregularities in patients with polycystic ovary syndrome: A systematic review of randomized trials","volume":"12","author":"Mrabet","year":"2024","journal-title":"SAGE Open Med"},{"key":"R28-20260302","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV Protection in the EMPA-REG OUTCOME Trial: A \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"R29-20260302","first-page":"CD003053","article-title":"Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility","volume":"11","author":"Morley","year":"2017","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_635_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:42:53Z","timestamp":1787773373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_635_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_635_25","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-07-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}